| Source: |
| Type: |
| Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms: 1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion. 2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue. 3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment. 4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream. 5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body. 6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection. 7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs. 8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis. |
| 1618- | EA, | A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action |
| - | Review, | BC, | NA |
| 7220- | EGb 761, | Ginkgo Biloba Extract Inhibits Metastasis and ERK/Nuclear Factor kappa B (NF-κB) Signaling Pathway in Gastric Cancer |
| - | vitro+vivo, | GC, | SGC-7901 |
| 6784- | EGCG, | Dietary (−)-Epigallocatechin Gallate (EGCG): State-of-the-Art Advances in Bioactivities, Bioavailability Enhancement Strategies, and Applications in Nutrition and Health |
| - | Review, | Nor, | NA |
| 4685- | EGCG, | Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines |
| - | in-vitro, | NPC, | TW01 | - | in-vitro, | NPC, | TW06 |
| 1503- | EGCG, | Epigenetic targets of bioactive dietary components for cancer prevention and therapy |
| - | Review, | Var, | NA |
| 22- | EGCG, | Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics |
| - | in-vitro, | PC, | CD133+ | - | in-vitro, | PC, | CD44+ | - | in-vitro, | PC, | CD24+ | - | in-vitro, | PC, | ESA+ |
| 1072- | EGCG, | Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways |
| - | in-vitro, | Thyroid, | 8505C |
| 665- | EGCG, | Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway |
| - | in-vitro, | Lung, | H1299 |
| 651- | EGCG, | Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications |
| - | Review, | Var, | NA |
| - | in-vitro, | PC, | NA |
| 6819- | EMD, | Recent advances in the therapeutic potential of emodin for human health |
| - | Review, | Nor, | NA |
| 6820- | EMD, | The Health Benefits of Emodin, a Natural Anthraquinone Derived from Rhubarb—A Summary Update |
| - | Review, | Nor, | NA | - | Review, | Arthritis, | NA | - | Review, | AD, | NA |
| 6823- | EMD, | Role of emodin to prevent gastrointestinal cancers: recent trends and future prospective |
| - | Review, | Var, | NA |
| 6833- | EMD, | Anticancer potential of emodin |
| - | Review, | Var, | NA |
| 1319- | EMD, | Emodin treatment of papillary thyroid cancer cell lines in vitro inhibits proliferation and enhances apoptosis via downregulation of NF‑κB and its upstream TLR4 signaling |
| - | in-vitro, | Thyroid, | TPC-1 | - | in-vitro, | Thyroid, | IHH4 |
| 1247- | EMD, | Emodin exerts antitumor effects in ovarian cancer cell lines by preventing the development of cancer stem cells via epithelial mesenchymal transition |
| - | vitro+vivo, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | A2780S |
| 6793- | EPA, | Contribution of Pyk2 pathway and reactive oxygen species (ROS) to the anti-cancer effects of eicosapentaenoic acid (EPA) in PC3 prostate cancer cells |
| - | in-vitro, | Pca, | PC3 |
| 6381- | Eug, | Biological Properties and Prospects for the Application of Eugenol—A Review |
| - | Review, | Var, | NA |
| 6386- | Eug, | A comprehensive and systematic review on potential anticancer activities of eugenol: From pre-clinical evidence to molecular mechanisms of action |
| - | Review, | Var, | NA |
| 6336- | Eug, | Eugenol induces apoptosis and inhibits invasion and angiogenesis in a rat model of gastric carcinogenesis induced by MNNG |
| - | in-vivo, | GC, | NA |
| 6338- | Eug, | Tumor suppressive roles of eugenol in human lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 6340- | Eug, | Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MDA-MB-231 |
| 6323- | Eug, | Eugenol: An Insight Into the Anticancer Perspective and Pharmacological Aspects |
| - | Review, | Var, | NA | - | Review, | Arthritis, | NA |
| 6331- | Eug, | Eugenol-Induced Autophagy and Apoptosis in Breast Cancer Cells via PI3K/AKT/FOXO3a Pathway Inhibition |
| - | in-vitro, | BC, | MDA-MB-231 |
| 6330- | Eug, | Molecular Mechanisms of Action of Eugenol in Cancer: Recent Trends and Advancement |
| - | Review, | Var, | NA |
| 6845- | EVO, | Evodiamine, a Novel NOTCH3 Methylation Stimulator, Significantly Suppresses Lung Carcinogenesis in Vitro and in Vivo |
| - | vitro+vivo, | NSCLC, | A549 | - | in-vitro, | Lung, | H1299 |
| 6846- | EVO, | Evodiamine Inhibits Colorectal Cancer Growth via RTKs Mediated PI3K/AKT/p53 Signaling Pathway |
| - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | HCT116 |
| 1111- | EVO, | Evodiamine exerts inhibitory roles in non‑small cell lung cancer cell A549 and its sub‑population of stem‑like cells |
| - | in-vitro, | Lung, | A549 |
| 6881- | FA, | Potential Therapeutic Efficacy of Ferulic Acid and Its Derivatives in the Management of Cancers: A Comprehensive Analysis With Mechanistic Insight |
| - | Review, | Var, | NA |
| 1654- | FA, | Molecular mechanism of ferulic acid and its derivatives in tumor progression |
| - | Review, | Var, | NA |
| 7513- | FA, | Anti-proliferative and anti-invasive effects of ferulic acid in TT medullary thyroid cancer cells interacting with URG4/URGCP |
| - | in-vitro, | Thyroid, | NA |
| 7512- | FA, | Ferulic acid decreases cell viability and colony formation while inhibiting migration of MIA PaCa-2 human pancreatic cancer cells in vitro |
| - | in-vitro, | PC, | MIA PaCa-2 |
| 7511- | FA, | The anticancer effects of ferulic acid is associated with induction of cell cycle arrest and autophagy in cervical cancer cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | CaSki |
| - | in-vitro, | Cerv, | NA |
| 6906- | FIS, | Rad, | Combining fisetin and ionizing radiation suppresses the growth of mammalian colorectal cancers in xenograft tumor models |
| - | in-vivo, | CRC, | CT26 | - | in-vivo, | CRC, | HCT116 |
| 6903- | FIS, | Involvement of the ERK signaling pathway in fisetin reduces invasion and migration in the human lung cancer cell line A549 |
| - | in-vitro, | Lung, | A549 |
| 6910- | FIS, | Exploring the therapeutic promise of fisetin: molecular mechanisms and clinical aspects in lung cancer |
| - | in-vitro, | Lung, | NA |
| 6915- | FIS, | SRF, | Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma |
| - | in-vitro, | Melanoma, | NA |
| 2847- | FIS, | Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells |
| - | in-vitro, | CCA, | NA |
| 2850- | FIS, | Fisetin regulates TPA-induced breast Cancer cell invasion by suppressing matrix metalloproteinase-9 activation via the PKC/ROS/MAPK pathways |
| - | in-vitro, | BC, | MCF7 |
| 2824- | FIS, | Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics |
| - | Review, | Var, | NA |
| 2829- | FIS, | Fisetin: An anticancer perspective |
| - | Review, | Var, | NA |
| 2839- | FIS, | Dietary flavonoid fisetin for cancer prevention and treatment |
| - | Review, | Var, | NA |
| 1113- | FIS, | Fisetin suppresses migration, invasion and stem-cell-like phenotype of human non-small cell lung carcinoma cells via attenuation of epithelial to mesenchymal transition |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 6980- | Form, | The potential role of formononetin in cancer treatment: An updated review |
| - | Review, | Var, | NA |
| 6982- | Form, | Formononetin: A Review of Its Anticancer Potentials and Mechanisms |
| - | Review, | Var, | NA |
| 6987- | Form, | Formononetin exhibits anticancer activity in gastric carcinoma cell and regulating miR-542-5p |
| - | vitro+vivo, | GC, | SGC-7901 | - | in-vitro, | BC, | MGC803 |
| 6970- | Form, | Formononetin, an isoflavone from Astragalus membranaceus inhibits proliferation and metastasis of ovarian cancer cells |
| - | in-vitro, | Ovarian, | NA |
| 6965- | Form, | Formononetin inhibits colon carcinoma cell growth and invasion by microRNA‑149‑mediated EphB3 downregulation and inhibition of PI3K/AKT and STAT3 signaling pathways |
| - | in-vitro, | CRC, | HCT116 |
| 6971- | Form, | In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa |
| - | vitro+vivo, | Cerv, | HeLa |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:324 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid